Archive · 21 Jan 2026
Venture Capitalists Rethink Healthtech Investments in India
Venture capitalists in India are changing how they invest in healthtech.
During the COVID-19 pandemic, many healthtech companies received a lot of money because more people were using digital health services.
Now, investors are being more careful.
They want to see that these companies are actually helping people and making money before they invest.
Big deals are still happening, but there are fewer smaller investments.
Investors are also interested in other areas like AI and fintech.
However, some new funds are still focusing on healthtech, especially those that make healthcare more affordable and accessible.
Healthtech investment in India is shifting from idea-led to execution-led, with investors focusing on proven solutions.
Deal volumes declined from 78 in 2024 to 54 in 2025, with total funding remaining around $700 Mn.
Major deals included Innovaccer's $275 Mn Series F round and PharmEasy's $192 Mn debt infusion.
Seed stage investments in healthtech decreased, with only 35 deals in 2025 compared to 47 in 2015.
Late stage funding increased from $400 Mn to $600 Mn, indicating selective investment in healthtech.
- Who
- Venture capitalists and healthtech startups in India
- What
- Shift in investment focus from broad platforms to proven solutions
- When
- 2025
- Where
- India
- Why
- Investors are seeking solutions with proven adoption and measurable impact
- Projected Market Growth
- 39% CAGR from 2025 to 2030, reaching $37 Bn+
- Deal Volume Decline
- From 78 in 2024 to 54 in 2025
- Total Funding
- Around $700 Mn in 2025
- Top Deals
- Innovaccer ($275 Mn), PharmEasy ($192 Mn)
- Seed Stage Deals
- 35 deals in 2025, down from 47 in 2015
- Late Stage Funding
- Increased from $400 Mn to $600 Mn
- New Funds Focused on Healthtech
- 16% of new funds in 2025
- Total New Fund Corpus
- $13.6 Bn in 2025, up 56% from 2024